CMSYX Fees and Costs — Adaptive Tactical Outlook Fund, Class C

Data updated: 2021-10-26

The net expense ratio is 2.37% (3.96% before fee waivers). This share class carries a deferred sales charge of up to 1.00%. In fiscal 2021 the fund paid $4K in broker commissions, 0.0355% of average net assets, and portfolio turnover was 144%.

CMSYX Fees and Expenses

Annual operating expenses and sales charges of CMSYX. Prospectus, as of May 31, 2021.

Annual operating expenses
Management fee1.00%
12b-1 fee1.00%
Other expenses1.84%
Gross expense ratio3.96%
Fee waiver−1.59%
Net expense ratio2.37%
Sales charges
Max front load0.00%
Max deferred load1.00%
Redemption fee0.00%
Expense limitation in place (N-CEN)Yes
Fees waived or reduced during the yearYes
Waived fees subject to recoupmentNo

CMSYX Costs Over Time

On $10,000 invested in CMSYX, assuming 5% a year before costs, total costs come to $1,463 over 5 years, cutting the return by 2.53% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Sales charges$102$0$0
Fund expenses (net expense ratio 2.37%)$249$765$1,307
Trading costs (broker commissions)$4$11$20
Lost growth on money paid in costs$0$39$136
Total costs$355$815$1,463
Value after costs$10,145$10,761$11,300
Impact on return, per year3.55%2.53%2.53%

CMSYX Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending May 31, 2021.

  • Explicit cost rate (commissions ÷ average net assets): 0.0355%
  • Total broker commissions: $4K
  • Bought from dealers (principal trades, not a cost): —
  • Portfolio turnover (prospectus): 144%
  • Securities lending: none during the year

CMSYX Agency Brokers

Commissions paid.

BrokerAmountShare
Wallachbeth Capital, LLC$4K100.00%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.